

Index

- administrative process theory,
 - health/trade conflict foundations and 85–7
 - advice *see* expert advice
 - aflatoxin 31, 33, 38, 93
 - Africa 31, 47
 - see also individually-named countries*; developing countries
 - Agreements
 - Agriculture 1994 (GATT) 35, 217
 - Application of Sanitary and Phytosanitary Measures, on the *see* SPS Agreement 1994
 - Marrakesh 1994 51
 - Standards Code 25–6, 289, 301
 - Technical Barriers to Trade, on (TBT Agreement 1994) 207, 301
 - see also* General Agreement on Tariffs and Trade; legislation
 - agricultural products
 - non-trade barriers rules' development and 26
 - tariff substitution and 35
 - WTO case *see Japan – Agricultural products*
 - see also* products
 - Alemanno, Alberto 174
 - Alma Alta Declaration (WHO 1978) 71
 - American Declaration on the Rights and Duties of Man 1948 71–2
 - anchoring
 - heuristics and bounded rationality, health/trade conflict foundations 89
 - animal health
 - defined 11
 - exposure assessment and 161
 - health/trade conflict and 18–20, 21, 22
 - protection, non-economic goals of health regulation and 74–7
 - public good, as 64–5
 - risk to health and 94, 98
 - science-based approach and 186
 - SPS Agreement disputes 32
 - WTO cases *see Australia – Salmon; EC – Hormones*
 - see also* health
 - appropriate level of protection
 - defined, SPS Agreement (Annex A(5)) 242–3
 - health (SPS Agreement Article 5.3) 105
 - right to set once risk presence established by scientific evidence and 29
- setting, risk management and 247–8
 - arbitrary/unjustifiable discrimination (SPS Agreement Article 2.3) 254, 256–62
 - GATT lessons 248–56
 - negative trade effects
 - minimization (SPS Agreement Article 5.4) 262–3
 - provisional measures and precautionary principle (SPS Agreement Article 5.7) 265–73
 - trade protection levels distinctions (SPS Agreement Article 5.5) 256–62
 - arbitrary/unjustifiable (SPS Agreement Article 5.6) 254, 263–5, 285–6
 - see also* health protection; trade protection
 - Argentina 16, 32, 33, 219, 222, 244–5
 - Atik, Jeffery 147, 151, 183, 192
 - attributes
 - content, food safety as force for change in SPS Agreement disputes and 37–9

- process, food safety as force for change in SPS Agreement disputes and 39–40
- Australia 16, 33, 36, 215, 230, 242
- Australia – Salmon*
analysis 241–31, 284–5, 287
facts 213–16
risk assessment and 245
risk management and 256, 260–62, 263–4, 281–3
- Australian Quarantine and Inspection Service (AQIS) 214
- availability
heuristics and bounded rationality, health/trade conflict foundations 88
- Avery, Natalie 26
- Baber, Zaheer 151
- Baldwin, Robert 90
- Baptist–Bootlegger theory 84, 141
- barriers *see* non-tariff barriers; trade barriers
- Beck, Ulrich 128
- Bhagwati, Jagdish 114–15, 116
- bias, normative *see* cultural cognition
- Blaine, James G. 20
- bounded rationality
cultural cognition compared 137–8
health/trade conflict foundations and 87–9
information deficits and, economic goals of health regulation and 65–6
- bounded self-interest, health/trade conflict foundations and 89
- bounded willpower, health/trade conflict foundations and 89
- Braman, Donald 136
- Brazil 32, 33, 125
- Brazil – Retreaded tyres*
analysis 230–31, 287
facts 222–4
risk management and 252, 254–5, 256
- Breton, Albert 117
- Britain *see* United Kingdom
- BSE *see* mad cow disease
- Bunge, M. 167
- burden of proof, SPS Agreement and 273–6
- Bureau, Jean-Christophe 43
- Burmester, Dr 281
- Busch, Lawrence 174–5
- Cairns Group 27
- Campbell, Faith Thomson 164
- Canada
Australia – Salmon and 214, 215
EC – Asbestos and 202, 207, 228, 249, 250
EC – Biotech products and 219, 222, 244–5
EC – Hormones and 209, 210, 213, 259, 266, 274
health protection measures as non-tariff barriers to trade and 14
health/trade disputes in 1800s 17, 21–2
risk analysis and 162, 166, 177
SPS measures' trade impact and 32
cancer, risk analysis and 162, 164
- Carozza, Paolo G. 111, 112, 113
- Carson, Rachel 127
- cascades
informational, risk perception and 134
reputational, risk perception and 134–5
- cases *see* decisions, case-based; health cases; health regulation, cases
- Cave, Martin 90
- Center for Disease Control and Prevention (CDC) (USA) 37, 164–5
- Chalmers, D. 174
- Chang, Howard F. 42–3, 99, 211
- Charters
African, on Human and Peoples Rights 1981 72
European Social 1961 72
World, for Nature (UN General Assembly Resolution 37/7) 75
see also legislation
- Charnovitz, Steve 200
- Chile 32
- China 32, 33, 38
- chlorpyrifos (pesticide), SPS measures' trade impact and 31

- cholera
 food safety and 37
 SPS measures' trade impact and 31
- Christoforou, Theofanis 283–4
- Coase, R.H. 62
- Codex Alimentarius Commission
 harmonization under SPS Agreement
 and 122, 123, 124
 mandating use of science
 domestically and 188
 regulatory harmonization and 121
 relevant international standards,
 guidelines and
 recommendations, as 28, 182
 SPS measures' trade impact and 31
 subsidiarity and 297
- cognition *see* cultural cognition
- Colombia, health protection measures as
 non-tariff barriers to trade and
 14–15
- Committee on Economic, Social and
 Cultural Rights (CESCR) 72–4
- Committee on SPS Measures *see* SPS
 Committee
- conflict *see* health/trade conflict; North-
 South conflict
- consistency proviso, scientific evidence
 requirements (SPS Agreement
 Article 2.2) and 182, 218, 222
- consumer surplus, gains from trade and
 55–6
- consumption possibility frontier, gains
 from trade and 55
- Conventions
 American, on Human Rights in the
 Area of Economic, Social and
 Cultural Rights San Salvador
 Protocol 1999 (OAS) 72
 Basel, Technical Guidelines on the
 Identification and Management
 of Used Tyres 230
 Bern, Conservation of European
 Wildlife and Natural Habitats
 75
 Biodiversity 75, 76
 Bonn, Conservation of Migratory
 Species of Wild Animals 76
 International Plant Protection (IPPC)
 29, 121, 122, 123, 124, 182,
 297
 International Trade in Endangered
 Species (CITES) 76
 Vienna, on the Law of Treaties 101,
 102
 Western Hemisphere 76
see also legislation
- Cosbey, Aaron 171–2
- costs
 information, standard setting and
 116–17
 Type I Error, health/trade conflict
 resolution and 103, 104
 Type II Error, health/trade conflict
 resolution and 103, 104
- Côte d'Ivoire 32
see also Africa
- Crawford-Brown, Douglas 166–7, 196
- Croley, Steven P. 81–3, 83–4, 85–7
- Cross, Frank B. 191
- Crump, Mr 20
- cultural cognition, risk perception and
 136–8
- Czech Republic 14
see also European Union
- Deane, Christine R. 134
- decision-making, right to participate in
 74
see also regulatory decision-making
- decisions
 case-based, heuristics and bounded
 rationality and, health/trade
 conflict foundations 89
- deficits
 information, bounded rationality and,
 economic goals of health
 regulation 65–6
see also information
- definitions
 affect 133
 animal health 11
 appropriate level of protection 242–3
 arbitrary 254–5
 autarky 54
 bounded rationality 66
 collective preferences 199
 community values 69
 economic regulation 60
 harmonization 121
 hazard identification 159

- health 10–12
- instrumental values 74–5
- international standards, guidelines or recommendations 122
- intrinsic values 75
- market failure 61
- minimum threshold of rationality 193
- necessary 250
- non-tariff barriers 12
- otherwise 182
- paternalism 67
- precautionary principle 169–70
- procedural conformity 193
- public health 10
- regulation 58
- regulatory harmonization 114
- risk 92
- risk assessment 157, 235–6, 241–2, 244, 271, 272, 273
- risk assessment which is adequate 270
- risk communication 155–6
- risk management 155, 168–9
- risks to human health 92–3
- sanitary or phytosanitary measures 28
- social regulation 60–61
- socially optimal level of protection 104–5
- sovereignty 111
- trans-science 152
- uncertainty 145–6
- unjustifiable 254–5
- welfare 95, 98
- Department of Agriculture (USA) 45
- Derry, Gregory N. 148, 151
- developed countries
 - health regulation and 69
 - health/trade conflict resolution and 106–7
 - non-trade barriers rules' development and 23–4
 - public participation in regulatory decision-making 40–43
 - risk perception in 127–9
 - scientific objectivity and 148
- developing countries
 - health/trade conflict resolution and 106–7
 - North-South conflict and 46–7
 - special needs (SPS Agreement Article 10) 107
 - SPS measures' trade impact 30–32, 33
 - standards, equivalence 125
 - subsidiarity and 298
- dioxins, risk analysis and 164–5, 165–6
- Directives
 - 81/602 (European Commission) 209
 - 90/220 (European Commission) 220
 - 2001/18 (European Commission) 219, 220
 - 2003/74/EC 213
 - see also* legislation
- discrimination
 - arbitrary/unjustifiable (SPS Agreement Article 2.3) 254, 256–62
 - disguised restriction on trade or (SPS Agreement Articles 2.3 and 5.5) 29, 103, 104, 157, 212, 215, 222
 - discriminatory measures justification (GATT Article XX) 7, 23, 117
 - see also* necessity test
- Disdier, Anne-Célia 30–31
- divergence *see* regulatory divergence
- dose-response assessment, risk assessment and 161
- Douglas, M. 166
- Dunkley, Graham 55, 56, 57, 100
- duties *see* obligations
- E.coli
 - food safety and 37
 - tariff substitution and 36
- EC *see* European Commission
- EC – *Asbestos*
 - analysis 226–7, 284, 287, 288
 - Canada and 202
 - facts 206–8
 - risk assessment and 228
 - risk management and 249–50, 251–2, 252–3, 279
- EC – *Biotech products*
 - analysis 244, 285, 287, 290
 - facts 218–22
 - health/trade conflict resolution and 101
 - risk management and 270–73

- EC – Hormones*
 analysis 227, 285, 286, 287, 289, 290
 facts 208–13
 risk assessment and 231–3, 236–41, 246–7
 risk management and 247
 burden of proof 274
 expert advice 279–81
 review standard 276, 277
 SPS Agreement 257, 259, 260, 262, 265–7
 science-based approach and 184
 standard setting and 122
- Echols, Marsha A. 184
- economics
 behavioural law and, health/trade
 conflict foundations 87
 case for trade and, health/trade
 conflict foundations 52–3
 goals, normative theories of health
 regulation and 61–6
 goals other than, normative theories
 of health regulation and
 66–77
 welfare, health regulation and 60
- The Economist* 38
- effects
 negative trade, minimization of (SPS
 Agreement Article 5.4) 29,
 103, 157, 262–3
- efficiency
 Kaldor-Hicks, gains from trade and
 53–4
 Pareto, gains from trade and 53, 54
- Egypt 125
see also Africa
- England *see* United Kingdom
- equivalence
 SPS Agreement (Article 4) 29, 125
 SPS Committee and 125
 standard setting 125
- Environmental Protection Agency (EPA)
 (USA) 45, 164, 165, 166, 189–90
- Euro-Retailer Working Group 15
- European Commission (EC)
 animal health definition and 11
EC – Biotech products and 220, 221,
 222
EC – Hormones and 209, 210, 211
 health definition and 10
 science-based approach and 288
see also European Union
- European Communities (EC) *see*
 European Union
- European Court of Justice 188
- European Food Safety Authority 173,
 174
- European Parliament 210, 211
- European Union (EU)
Brazil – Retreaded tyres and 222,
 223
 cases (WTO) *see EC – Asbestos; EC –
 – Biotech products; EC –
 – Hormones*
 Directives *see* legislation
 Japanese import exclusions from
 compulsory approval and 15
 meat cases (WTO) *see EC –
 – Hormones*
 non-trade barriers rules and 26, 27
 North-South conflict and 46, 47
 regulatory divergence and 43–4
 regulatory harmonization and 114,
 118
 risk analysis and 152–3, 173–4
 risk perception and 132
 SPS measures' trade impact and 31,
 32, 33
 standards, equivalence 125
 subsidiarity principle and 112–13
 tariff substitution 36
*see also individually named Member
 States; European Commission*
- evidence *see* relevant evidence
 requirements; scientific evidence
- exclusion
 imported products from compulsory
 approval, as non-tariff barrier
 to trade 14–15
- expert
 risk perception by, public perception
 contrasted 129–30
- expert advice
 science-based approach and 196–7
 SPS Agreement and 273, 278–84
- exposure assessment, risk assessment
 and 161–3
- externalities
 negative, economic goals of health
 regulation and 61–3

- Farina, Cynthia R. 90
- Feinberg, Joel 67–8
- Feintuck, Mike 77–8
- Ferrières, Madeleine 21
- flora and fauna *see* animal health; plant health
- Fontagné, Lionel 30–31
- food safety
 - health cases analysis and 288–9
 - health/trade conflict and 19–21
 - non-tariff barriers to trade and 13, 14–15
 - regulatory divergence and 43–4
 - risk to health and 94, 98–9
 - science-based approach and 184
 - SPS Agreement disputes and 32, 36–40
 - SPS Committee and 38–9
 - standard setting and 124
 - WTO cases *see* *Australia – Salmon; EC – Biotech products; EC – Hormones; Japan – Agricultural products; Japan – Apples*
see also human health
- foot and mouth disease, import prohibitions and 13
- France
 - Australian tariff substitution and 36
 - EC – Asbestos* and 206–8, 228, 229, 249, 250, 251
 - EC – Hormones* and 208
 - health/trade disputes in 1800s 16, 17–18, 19, 21–2
 - see also* European Union
- free trade objections, health/trade conflict foundations and 56–8
see also trade
- G-90 *see* developing countries
- gains from trade, health/trade conflict foundations and 53–6
see also trade
- The Gambia 32
see also Africa
- Garcia, Frank J. 264
- General Agreement on Tariffs and Trade 1947 (GATT)
 - Article I 23, 30
 - Articles III and III:4
like products 208, 226
 - national treatment obligation 23, 30, 117, 204, 223, 226
- Article XI 30
- Article XI.1 23, 204, 206
- Article XX
 - discriminatory measures
justification 7, 23, 117
 - necessity test 229, 254, 255, 257, 263
- Article XX(a) 188, 301
- Article XX(b)
 - Brazil – Retreaded tyres* and 223
 - EC – Asbestos* and 208
 - interpretation by dispute panels
and/or Appellate Body 284
 - regulatory harmonization and 117
 - risk assessment and 228–9
 - risk management and 248–9, 250, 254
 - science-based approach and 181, 188
 - SPS Agreement alongside 30
 - Thailand – Cigarettes* and 204, 206, 225
- Article XX(d) 250
- Article XX(g) 101, 117
- Australia – Salmon* and 214
- case for trade and 51
- Japan – Agricultural products* and 217
- Japan – Apples* and 218
- non-trade barriers rules and 25, 26
- primary focus 23, 293
- risk assessment and 228–31
- risk management and 248–56
- SPS Agreement contrasted 7
- science-based approach and 181, 188
- standard setting and 122
see also Agreements; World Trade Organization
- genetically modified (GM) foods
 - health cases analysis and 287–8
 - risk to health and 94, 98
 - risk perception and 132, 140
 - see also* food safety; human health
- Germany 17, 19, 20, 170
see also European Union
- Gignilliat, John L. 20–21
- Gostin, Lawrence O. 64, 68, 70
- Green, Andrew J. 42

- Hahn, Robert 139
- harmonization
 defined 121
 SPS Committee role 122–3
 subsidiarity and 297–8
see also regulatory harmonization
- Hartley, Sarah 152, 153
- Hassan, Ayesha 210–11
- Hayden, S.S. 75
- hazard identification
 default assumptions and 165
 risk assessment and 159–61
- health
 defined 10–12
 international trade link 9
 objectives *see* health/trade objectives
 protection measures as non-tariff
 trade barriers 12–15
 right to 70–74
see also animal health; human health;
 plant health; public health
- health cases
 analysis 225
 key points 284–90
 normative approach 225–7, 284
 SPS Agreement interpretation *see*
 SPS Agreement
- Australia – Salmon* 213–16
- Brazil – Retreaded tyres* 222–4
- ‘difficult’, identifying 95–9
- EC – Asbestos* 206–8
- EC – Biotech products* 218–22
- EC – Hormones* 208–13
- identifying 92
- Japan – Agricultural products*
 216–17
- Japan – Apples* 218
- Thailand – Cigarettes* 202, 204–6
- health protection
 necessity exception and (GATT
 Article XX (b)) 30, 117, 181,
 188, 284
- Brazil – Retreaded tyres* and
 223
- EC – Asbestos* and 208
- risk assessment and 228–9
- risk management and 248–9, 250,
 254
- Thailand – Cigarettes* and 204,
 206, 225
- socially optimal level of, defined
 104–5
see also appropriate level of
 protection; trade protection
- health protection measures
 non-tariff trade barriers, as 12–15
 right to take necessary (SPS
 Agreement Article 2.1) 181–2,
 248
see also measures
- health regulation
 cases 203
 health/trade conflict foundations and
 58–60
 alternative explanations 85–90
 normative theories 60–61, 293–4
 economic goals 61–6
 non-economic goals 66–77
 private interest theory, public
 choice and 79–85
 public interest theory 77–9
 SPS Agreement and 59, 74, 76–7, 85
see also regulation; rules
- health risk
 health cases analysis and 290
 health/trade conflict identification
 and 92–4
- health/trade conflict
 1800s 16–23
 aims of present study 5–6
 foundations 51, 90–91, 293
 health regulation *see* health
 regulation
- trade, case for 51–2
 economic 52–3
 free trade, objections to 56–8
 gains from trade 53–6
- identification
 ‘difficult’ cases 95–9
 risk to health 92–4
 SPS Agreement and 95, 99
- non-trade barriers, rules development
 23–8
- resolution
 GATT Article XX(b) 117, 181,
 188, 208, 223, 248–9, 250,
 254, 284
 GATT Article XX(g) exception
 and 101, 117
 normative framework 102–7

- SPS Agreement and 100, 101, 102, 103, 106, 107
- WTO and international law rules 100–102
- SPS Agreement and 3, 4, 28–32, 91
- SPS Agreement disputes 32–3, 34
- health/trade objectives
 - conflict between 96–7
 - normative basis for balance of 294–7
- Heijnsbergen, P. van 76
- Heschl, Richard 19
- heuristics
 - bounded rationality and 88–90
 - risk perception and 130–34
- Hobbs, J.E. 260
- hormones *see EC – Hormones*
- Howse, Robert
 - health/trade conflict resolution and 102
 - science-based approach and 186–7, 198
 - SPS Agreement interpretation and 235, 251, 252
 - SPS Agreement science-based framework and 301
 - standard-setting and 115–16, 117–18
- Hrudey, Steve E. 171, 172
- Hudec, Robert 6–7
- human health
 - dose-response assessment and 161
 - exposure assessment and 161
 - hazard identification and 160–61
 - protection obligation, non-economic goals of health regulation and 70–74, 103
 - risk perception and 134
 - risk to health and 93–4
 - risks to, defined 92–3
 - science-based approach and 186
 - uncertainty and 164
 - WTO cases *see Brazil – Retreaded tyres; EC – Asbestos; EC – Biotech products; EC – Hormones; Thailand – Cigarettes*
 - see also* food safety; health; public health
- human rights
 - health 70–74
 - participate in decision-making 74
 - see also* rights
- Iacavone, Leonardo 30
- identification *see* hazard identification; health/trade conflict, identification
- imports
 - exclusion from compulsory approval as non-tariff barrier to trade 14–15
 - prohibitions as non-tariff barrier to trade 13–14
 - see also* products
- India 33
- Indonesia 33
- information, standard setting and 116–17
 - see also* cascades, informational; costs, information; deficits, information
- interest *see* bounded self-interest; private interest theory; public interest theory
- international law
 - rules, WTO and, health/trade conflict resolution 100–102
 - see also* law
- International Legal Commission (ILC) 101
- International Office of Epizootics/International Animal Health Organization (OIE)
 - Australia – Salmon* and 214, 242
 - harmonization under SPS Agreement and 122, 123, 124
 - regulatory harmonization and 121
 - relevant international standards, guidelines and recommendations, as 29, 182
 - subsidiarity and 297
- international organizations, SPS Committee contact with (SPS Agreement Article 12.3) 122–3
- international standards
 - guidelines or recommendations, defined 122
 - higher trade protection level than implied in (SPS Agreement Article 3.3) 29, 122, 182
 - international trade, health link 9

- Italy 19, 208
see also European Union
- Japan 15, 27, 33
Japan – Agricultural products
 analysis 233, 234, 235, 287
 facts 216–17
 risk management and 264, 268, 270,
 274–5, 275–6, 279
- Japan – Apples*
 analysis 233–4, 234–5, 285, 287
 facts 218
 risk assessment and 243–4
 risk management and 268–9, 270,
 271, 275, 277
- Jardine, Cindy G. 177
- Jasanoff, Sheila 45–6, 140, 145, 146,
 147, 165
- JECFA Reports 212, 237
- Johannes Althusius 112
- Jolls, Christine 87, 89
- Josling, Tim 36, 104–5, 210–11
- justice
 distributive, non-economic goals of
 health regulation and 66–7
- Kagan, Robert A. 59
- Kahan, Dan M. 136, 137, 138, 140
- Kenya 31–2
see also Africa
- Kerr, William A. 154, 260
- Kimbell, A.M. 31
- Korea 14, 33
- Korea – Beef* 250, 263, 288
- Kraemer, Helena Chmura 92–3
- Kraemer-Lowe, Karen *see* Lowe, Karen
 Kraemer-
- Kuhn, Thomas S. 149
- Kupfer, David J. 92–3
- Lamming Report 212, 237
- Lamy, Pascal 199–200
- law
 behavioural, economics and,
 health/trade conflict
 foundations 87
 science and 143–6
see also international law
- lawyers, scientific illiteracy of 146
- lead, risk to health and 94
- Leebron, David W. 114, 116, 119, 124
 legislation
 Act to Prohibit the Manufacture and
 Sale of Certain Substitutes for
 Butter (Canada) 22
 Corn Laws (England) 17
 Decree No. 96-1133 (France) 206
 Executive Order 12866 of 1993
 (USA) 189
 Federal Meat Inspection Act 1906
 (USA) 84
 Foreign Animals Order 1878 (Great
 Britain) 18–19
 International Covenant on Civil and
 Political Rights 1948 (ICCPR)
 (UN) 74, 101
 International Covenant on Economic,
 Social and Cultural Rights
 1966 (ICESCR) (UN) 71, 72,
 101, 102
 Meat Inspection Act 1891 (USA) 21
 Quarantine Proclamation 86A
 (QP86A) 1975 (Australia)
 213–14
 Regulation 258/97 (European
 Commission) 219, 220
 Tobacco Act 1966 (Thailand) 204,
 205
 Understanding on Rules and
 Procedures Governing the
 Settlement of Disputes
 (Dispute Settlement
 Understanding (DSU)) 213,
 234, 276–7, 278–9
see also Agreements; Charters;
 Conventions; Declarations;
 Directives; rules; Treaties
- Leiss, William 171, 172
- level of protection *see* appropriate level
 of protection; health protection;
 trade protection
- Lindseth, Peter L. 40–41
- Lowe, Karen Kraemer- 92–3
- Lowrance, William W. 128, 150–51
- mad cow disease (BSE)
 health cases analysis and 288
 import prohibitions and 13
 regulatory divergence and 45
 risk perception and 134, 135

- Marette, Stephan 43
 margarine, health/trade conflict and 21–2
 margarine, health/trade conflict and 21–2
 market failure
 defined 61
 economic goals of health protection and
 information deficits and bounded
 rationality 65–6
 negative externalities 61–3
 public goods 63–5
 non-economic goals of health
 regulation and
 animal and plant health protection
 74–7
 community values 69–70
 distributive justice 66–7
 human health protection
 obligation 70–74
 paternalism 67–9
 McGarity, Thomas O. 193–5
 measures
 based on SPS Agreement (Article 3.1) 121–2, 182, 212
 SPS Committee encouraging
 Members to take (Article 12.2) 122
 conforming to SPS Agreement (Article 3.2) 122
 sanitary or phytosanitary, defined 28
 see also health protection, measures;
 provisional measures; SPS
 measures
 mechanisms
 psychological *see* heuristics
 social, risk perception and 134–6
 media, risk perception and 135–6
 Mège-Mouriés, Hippolyte 21
 MERCOSUR countries 223, 224, 256
 Mexico 13, 33
 Michaels, David 153–4
 Mimouni, Mondher 30–31
 Ministry of Agriculture, Fisheries and Food (UK) 45
 Ministry of Agriculture, Forestry and Fisheries (Japan) 216
 Monforton, Celeste 153–4
 most favoured nation obligation (GATT Article I) 23, 30
 Mozambique 31–2
 see also Africa
 mutual recognition *see* equivalence
 National Research Council (NRC) (USA) 164, 168–9, 173, 174, 175, 177, 184
 national treatment obligation (GATT Articles III and III:4) 23, 30, 117, 204, 223, 226
 Neal, Mark 128–9
 necessity exception
 health protection and (GATT Article XX (b)) 30, 117, 181, 188, 284
 Brazil – Retreaded tyres and 223
 EC – Asbestos and 208
 risk assessment and 228–9
 risk management and 248–9, 250, 254
 Thailand – Cigarettes and 204, 206, 225
 public morals and (GATT Article XX (a)) 188
 necessity test, (GATT Article XX) 229, 254, 255, 257, 263
 see also discriminatory measures
 justification
 Neumann, Jan 263
 New Zealand 36
 non-tariff barriers
 defined 12
 health protection measures as 12–15
 SPS Agreement and 293
 see also General Agreement on
 Tariffs and Trade; tariff
 substitution; trade barriers
 North America *see* United States of America
 North-South conflict 46–7
 objectivity
 lack of, science-based approach and 183–4
 notion of, science and risk analysis and 147–55
 see also rationality threshold;
 scientific objectivity
 objectives *see* health/trade objectives
 obligations
 human health protection 70–74, 103

- most favoured nation (GATT Article I) 23, 30
- national treatment (GATT Articles III and III:4) 23, 30, 117, 204, 223, 226
- organizations *see* international organizations
- Ogus, Anthony I. 65–6, 67, 68, 69, 70, 79
- OIE *see* International Office of Epizootics/International Animal Health Organization
- Orden, David 36, 104–5
- Organization of American States (OAS) 72
- Organization for Economic Cooperation and Development (OECD) 24, 31
- Otsuki, Tsunehiro 31
- outcome, risk to health and 93
- ozone-depletion, science-based approach and 189
- Panama 33
- paternalism, non-economic goals of health regulation and 67–9
- Paustenbach, Dennis J. 163
- Pauwelyn, Joost 166–7, 196, 262
- Peel, Jacqueline 186
- Perdikis, N. 220
- Perez, Oren 8, 186
- Perren, John 19
- Pfouts, R.W. 55–6
- phyloxera vastatrix, health/trade conflict and 17–18
- Pimenta Report 210
- Pius XI, Pope 112
- plant health
 - exposure assessment and 161
 - health/trade conflict and 17–18
 - non-tariff barriers to trade and 13, 15
 - protection, non-economic goals of health regulation and 74–7
 - public good, as 64, 65
 - regulation 12
 - risk to health and 94
 - science-based approach and 186
 - SPS Agreement disputes 32
 - uncertainty and 164
 - see also* health
- pleuro-pneumonia, health/trade conflict and 18–19
- polychlorinated biphenyls (PCBs), science-based approach and 194
- population, risk to health and 93
- positive requirements, as non-tariff barrier to trade 14
- Posner, Richard A. 146, 154
- Powell, Mark R. 164, 166, 167, 189–90
- precaution, science and risk analysis and 169–73
- precautionary principle
 - defined 169–70
 - provisional measures and (SPS Agreement Article 5.7) 265–73
 - SPS Agreement interpretation by dispute panels and/or Appellate Body and 303–4
- Prévost, Denise 277
- private interest theory
 - public choice and, positive theories of health regulation and 79–85
- probability
 - health cases analysis and 287–8
 - health/trade conflict resolution and 102, 104
 - risk to health and 93
- probability neglect, risk perception and 131
- products
 - biotech *see* EC – Biotech products like (GATT Articles III and III:4) 208, 226
 - see also* agricultural products; imports
- protection *see* appropriate level of protection; health protection; trade protection
- protectionism
 - gains from trade and 56
 - health cases analysis and 290
 - health/trade conflict and 20–21, 22, 23
 - risk to health and 99
 - science-based approach and 186
- provisional measures
 - SPS Agreement (Article 5.7) 217, 218, 222
 - precautionary principle and 265–73

- right in absence of sufficient scientific evidence to take 183
 - see also* measures
- public
 - participation in regulatory decision-making, as force for change for SPS Agreement disputes 40–43
 - risk analysis role 175–8
 - risk perception *see* risk perception, public and
- public choice
 - private interest theory and, positive theories of health regulation and 79–85
- public goods, economic goals of health regulation and 63–5
- public health
 - defined 10
 - food safety and 37
 - health/trade conflict and 17, 18, 19, 20, 21–2
 - public good, as 64
 - see also* health; human health
- public interest theory, positive theories of health regulation and 77–9
- public morals, necessity exception and (GATT Article XX (a)) 188, 301
- public sentiment
 - health/trade conflict resolution and 102
 - science-based approach and 186, 190–91, 198–201
- Rachlinski, Jeffrey J. 83, 90
- rationality *see* bounded rationality; objectivity; scientific objectivity
- rationality threshold, science-based approach and 193–6
- refrigeration, health/trade conflict and 16–17
- regulation
 - defined 58
 - economic, defined 60
 - mixed motives for 99, 102
 - response to public risk perception, as 139–41
 - social, defined 60–61
 - see also* health regulation; rules
- regulatory decision-making
 - domestic, reviewing, science-based approach and 191–201
 - public participation in, as force for change for SPS Agreement disputes 40–43
 - SPS Agreement and 42, 293
 - subsidiarity and 297–8
 - see also* decision-making
- regulatory divergence
 - SPS Agreement disputes, as force for change for 43–6
- regulatory harmonization
 - defined 114
 - standard setting and arguments for and against 114–21
 - defined 113–14
 - SPS Agreement, under 121–4
 - see also* harmonization
- regulatory sovereignty
 - risk tolerance, in respect of 29
- relevant evidence requirements (SPS Agreement Article 5.2), risk assessment and 246–7, 265, 266, 267, 283, 285
- restrictions
 - qualitative, (GATT Article XI) 30
 - quantitative (GATT Article XI.1) 23, 204, 206
- review standard, SPS Agreement and 273, 276–8
- Reynolds, Christopher 70
- Ricardo, David 52
- rights
 - set appropriate level of protection once risk presence established by scientific evidence 29
 - take measures necessary to protect health (SPS Agreement Article 2.1) 181–2, 248
 - take provisional measures in absence of sufficient scientific evidence (SPS Agreement Article 5.7) 183
 - see also* human rights
- Rio Declaration (UN 1992) 101, 170
- risk, defined 92
 - see also* health risk
- risk analysis
 - public role in 175–8

- science and 143
 - objectivity notion 147–55
 - precaution 169–73
 - values and 155–7
- SPS Agreement and 143, 145, 147, 154, 157, 173, 175
 - see also* risk management
- risk assessment
 - defined 157, 235–6, 241–2, 244, 271, 272, 273
 - GATT lessons 228–31
 - health/trade conflict resolution and 103, 105–6
 - precaution in 172
 - qualitative 158, 159
 - quantitative 158–9
 - rationality of 166–7
 - requirements (SPS Agreement Article 5.1) 29, 235–45
 - Australia – Salmon* and 215
 - discrimination/disguised restrictions and distinctions in level of protection and 261
 - EC – Biotech products* and 222
 - EC – Hormones* and 212
 - expert advice and 283
 - Japan – Apples* and 218
 - provisional measures and precautionary principle and 265, 266, 267, 269, 272, 273
 - public risk perception and 288
 - science-based approach and 182
 - relevant evidence requirements 246–7, 265, 266, 267, 283, 285
 - risk management distinguished 173–5, 246
 - science and risk analysis and 157–68
 - scientific evidence requirements (SPS Agreement Article 2.2) 231–5, 267, 268, 270, 277, 288
 - which is adequate, defined 270
- risk management
 - defined 155, 168–9
 - health/trade conflict resolution and 103–4
 - precaution in 172
 - risk assessment distinguished 173–5, 246
 - science and risk analysis and 168–9
 - setting appropriate level of protection
 - see* appropriate level of protection, setting
 - see also* risk analysis
 - risk perception
 - health cases analysis and 288–9
 - health/trade conflict and 22
 - public and 127
 - cultural cognition or ‘normative bias’ 136–8
 - psychological mechanisms (heuristics) 130–34
 - regulating in response to 139–41
 - social mechanisms 134–6
 - WTO and 141–2
 - public/expert 105, 129–30, 288
 - Western society, in 127–9
 - risk tolerance, regulatory sovereignty in respect of 29
 - Roberts, Donna 36, 104–5, 210–11
 - Rodgers, Dr 281, 283
 - rules
 - international law, WTO and, health/trade conflict resolution 100–102
 - non-trade barriers, health/trade conflict and 23–8
 - see also* health regulation; legislation; regulation
 - St Vincent and the Grenadines 15
 - salmonellosis, food safety and 37
 - Sandford, Ian 27–8
 - Schumacher, E.F. 57–8, 62, 100, 106
 - Science* 189
 - science
 - domestic use of, mandating 188–90
 - junk, scientific objectivity and 153–4
 - lack of objectivity, science-based approach and 183–4
 - law and 143–6
 - risk analysis and *see* risk analysis, science and
 - trans-, scientific objectivity and 153
 - values and, relationship between 151
 - science-based approach, SPS Agreement and criticisms of 184–5, 186–7

- mandating use of science
 - domestically 188
- domestic regulatory decisions review
 - 195, 196, 198, 199, 201
- scientific evidence requirements
 - 181–3
- validating 190, 191
- scientific evidence
 - Australia – Salmon* and 283
 - ‘available’ 29
 - criticism 4–5
 - EC – Hormones* and 246–7, 265, 266, 285
 - insufficiency of 269
 - requirements (SPS Agreement Article 2.2)
 - consistency proviso 182, 218, 222
 - risk assessment and 231–5, 267, 268, 279, 270, 277, 288
 - risk analysis and 157
 - sufficient, right to take provisional measures in absence of (SPS Agreement Article 5.7) 183
- scientific objectivity
 - junk science and 153–4
 - science-based approach and 185–6
 - trans-science and 153
 - see also* objectivity; rationality
 - threshold
- scientific uncertainty
 - health cases analysis and 289–90
 - health/trade conflict resolution and 102
 - risk to health and 99
 - science-based approach and 189–90, 198
 - see also* uncertainty
- Scott, C. 58
- Scott, Dayna Nadine 184
- Scott, Joanne 184–5
- self-interest *see* bounded self-interest
- Senegal 32
 - see also* Africa
- Sinclair, Upton 84
- Sjoberg, Lennart 131
- Skogstad, Grace 152, 153, 199
- Slovic, Paul 130–31, 132, 135, 139–40, 141, 176
- Smith, Kelly 166–7, 196
- society
 - risk, risk perception and 128–9
 - Western *see* developed countries
- Sokal, Alan D. 149–50
- Soloway, Julie 9, 84, 191, 192, 277, 278
- sovereignty *see* regulatory sovereignty
- spongiform encephalopathy *see* mad cow disease; transmissible spongiform encephalopathy
- SPS Agreement 1994
 - adoption of 3
 - Annex A 122
 - Annex A(2) 121
 - Annex A(4) 157, 235–6, 241–2, 244, 271, 272, 273
 - Annex A(5) 242–3
 - Article 2.1 181–2, 248
 - Article 2.2
 - consistency proviso 182, 218, 222
 - risk assessment and 231–5, 267, 268, 270, 277, 288
 - Articles 2.3 and 5.5
 - appropriate level of protection and 29
 - Australia – Salmon* and 215
 - EC – Biotech products* and 222
 - EC – Hormones* and 212
 - GATT chapeau and 254
 - health case analysis generally and 256–62
 - health/trade objectives and 103, 104
 - risk analysis and 157
 - risk perception and 288
 - Article 3.1 121–2, 182, 212
 - Article 3.2 122
 - Article 3.3 29, 122, 182
 - Article 3.4 122
 - Article 4 29, 125
 - Article 5 246
 - Article 5.1
 - Australia – Salmon* and 215, 261, 283
 - EC – Biotech products* and 222, 272, 273
 - EC – Hormones* and 212, 265, 266, 267
 - interpretation by WTO and 303
 - Japan – Apples* and 218, 269
 - risk assessment requirements and 29, 235–45

- risk perception and 288
- science-based framework and 300
- scientific evidence requirements and 182
- Article 5.2
 - Australia – Salmon* and 283
 - criticism 4–5
 - EC – Hormones* and 265, 266, 285
 - health case analysis generally and 246–7
 - interpretation by WTO and 302–3
 - risk analysis and 157
 - scientific evidence requirements and
 - ‘available’ 29
 - consistency proviso 182, 218, 222
 - risk assessment and 231–5, 267, 268, 279, 277, 288
- Article 5.3 105, 288
- Article 5.4 29, 103, 157, 262–3
- Article 5.5 *see* Articles 2.3 and 5.5 *above*
- Article 5.6
 - appropriate level of protection and 29–30
 - Australia – Salmon* and 215
 - EC – Biotech products* and 222
 - GATT chapeau and 254
 - health case analysis generally and 263–5
 - health/trade objectives and 103, 104
 - interpretation by dispute panels and/or Appellate Body and 303
 - Japan – Agricultural products* and 217
 - risk analysis and 157
 - risk management and 285–6
- Article 5.7 183, 217, 218, 222, 265–73, 303–4
- Article 7 217
- Article 10 107
- Article 11.1 273, 278–84
- Article 12 32
- Article 12.2 122
- Article 12.3 122–3
- Article 12.4 123
- burden of proof 273–6
- disputes under *see* SPS Agreement
 - disputes
 - draft of 26–8
 - EC – Asbestos* and 227, 302
 - EC – Biotech products* and 219
 - EC – Hormones* and 209, 212, 227, 302–3
- GATT contrasted 7
- health/trade conflict and 3, 4, 28–32, 91
 - aims of present study 5–6
 - case for trade 52, 57
 - health regulation 59, 74, 76–7, 85
 - identification 92, 93–4, 95, 99
 - necessity determination
 - privileging health 4
 - resolution 100, 101, 102, 103, 106, 107
- interpretation of
 - dispute panels and/or Appellate Body by 302–4
 - flexibility 305
- Japan – Agricultural products* and 217
- negotiation of 26
- non-tariff barriers and 293
- North-South conflict and 47
- objectives of 3–4, 28
 - regulatory divergence in achieving same 5
- outline of present study and 7–8
- ‘post-discriminatory’ nature of 7
- regulatory decision-making and 42, 293
- review standard 273, 276–8
- risk analysis and 143, 145, 147, 154, 157, 173, 175
- risk perception 127, 130, 141
 - public/expert (Article 5.3) 105, 288
- risk tolerance, regulatory sovereignty in respect of 29
- sanitary or phytosanitary measures, defined 28
- science-based approach and
 - criticisms of 184–5, 186–7, 298–301
 - mandating use of science domestically 188

- domestic regulatory decisions
 - review 195, 196, 198, 199, 201
 - scientific evidence requirements 181–3
 - validating 190, 191
- standard setting and 111, 113, 119, 120, 121–4, 126
- subsidiarity and 297, 298
- see also* Agreements; World Trade Organization
- SPS Agreement disputes
 - forces for change for 35, 48
 - food safety 36–40
 - North-South conflict 46–7
 - regulatory decision-making, public participation in 40–43
 - regulatory divergence 43–6
 - tariff substitution 35–6
- health/trade conflict and 32–3, 34
- SPS Committee
 - equivalence and 125
 - harmonization role 122–3
 - encouraging Members to base measures on Agreement (Article 12) 122
 - establishment of 32
 - food safety and 38–9
- SPS measures
 - publication requirement (SPS Agreement Article 7) 217
 - WTO Committee on (SPS Agreement Article 12) 32
 - see also* measures
- standard setting
 - mutual recognition 125
 - regulatory harmonization
 - arguments for and against 114–21
 - defined 113–14
 - SPS Agreement, under 121–4
 - SPS Agreement and 111, 113, 119, 120, 121–4, 126
 - subsidiarity principle 112–13
- standards *see* international standards; standards
- Standards Code
 - adoption of 25
 - deficiencies in 25–6
 - objectives of 25
 - risk perception and 289
 - SPS Agreement science-based framework and 301
 - unnecessary obstacles to international trade (Art 2.1) 25
 - see also* Agreements; legislation
- Stigler, George J. 79
- Stockholm Declaration (UN 1972) 76
- subsidiarity
 - harmonization and 297–8
 - standard setting and 112–13
- substitution *see* tariff substitution
- Sunstein, Cass R.
 - health/trade conflict foundations and 66, 69, 87, 88, 89
 - public interest theory and 79
 - public risk perceptions and WTO and 141
 - regulatory decision-making and 42
 - risk analysis and 170–71
 - risk perception and 127, 131, 132–4, 134–5, 137–8, 140–41
- Swinbank, Alan 125
- Switzerland 36, 125
- Sykes, Alan O.
 - health/trade conflict foundations and 53–5, 56
 - science-based approach and 183
 - scientific evidence requirements and 5
 - SPS Agreement Article 5.6 and 264
 - standard setting and 114, 120–21, 122
- Taneda, K. 31
- Tanzania 31–2
 - see also* Africa
- tariff substitution
 - disputes under SPS Agreement, as force for change for 35–6
 - see also* non-tariff barriers
- TBT Agreement 1994 *see* Standards Code
- Teitel, Ruti G. 102
- Thailand 32
- Thailand – Cigarettes*
 - analysis 225–6, 287
 - facts 202, 204–6
 - risk assessment and 228
 - risk management and 248–9
- Thaler, Richard 87, 89

- Thomas Aquinas, Saint 112
The Times 19, 20
Toronto Globe 21–2
- trade
 case for, health/trade conflict foundations and 51–2
 economic 52–3
 free trade, objections to 56–8
 gains from 53–6
 disguised restriction on,
 discrimination or (SPS Agreement Article 2.3 and 5.5) 29, 103, 104, 157, 212, 215, 222
 international, health link 9
 negative effects, minimization of (SPS Agreement Article 5.4) 29, 103, 157, 262–3
 objectives *see* health/trade objectives
- trade barriers
 non-, rules development 23–8
 TBT Agreement *see* Standards Code
see also non-tariff barriers
- trade protection
 arbitrary/unjustifiable (SPS Agreement Article 5.6)
 appropriate level of protection and 29–30
Australia – Salmon and 215
EC – Biotech products and 222
 GATT chapeau and 254
 health case analysis generally and 263–5
 health/trade objectives and 103, 104
Japan – Agricultural products and 217
 risk analysis and 157
 risk management and 285–6
 distinctions in levels of (SPS Agreement Article 5.5) 256–62
 higher level than implied in international standards (SPS Agreement Article 3.3) 29, 122, 182
see also appropriate level of protection; health protection
- transmissible spongiform encephalopathy (TSE), SPS Agreement disputes 32
- Treaties
 Commercial, 1860 (Anglo-French) 17
 Treaty of Amsterdam 1997 (European Union) 188
 Treaty of Rome 1957 (EC Treaty) 112–13, 188–9
see also legislation
- Trebilcock, Michael
 health and international trade link and 9
 health/trade conflict foundations and 68, 83, 90–91
 review standard and 277, 278
 science-based approach and 191, 192
 standard setting and 115–16, 117–18
 trichinella spiralis, health/trade conflict and 19–20, 21, 22
- Tuerk, Elizabeth 251, 252, 263
- Tyler, Tom 41
- Uganda 31–2
see also Africa
- uncertainty
 risk analysis and 145–6, 163–4
 trans-science, as 152
see also scientific uncertainty
- Unilever Canada Inc. 22
- United Kingdom (UK)
 health/trade disputes in 1800s 16, 17, 18, 19, 20, 22
 health regulation and 59
 regulatory divergence and 45
 risk analysis and 153
 risk perception and 134, 135
see also European Union
- United States of America (USA)
EC – Biotech products and 218, 220, 222
EC – Hormones and 209, 210, 211, 213
 gasoline cases (WTO) *see* *US – Reformulated Gasoline*
 health/trade disputes in 1800s 16, 17, 18, 19, 20, 21, 22
 health regulation and 59, 62, 84
 import prohibitions, health protection measures as non-tariff barriers to trade 13
Japan – Agricultural products and 216, 217

- Japan – Apples* and 218
 non-trade barriers rules and 26, 27
 North-South conflict and 46, 47
 regulatory decision-making 42
 regulatory divergence and 43, 44, 45
 regulatory harmonization and 115, 124
 risk analysis and 153, 158, 162, 164–6, 170
 risk assessment and 230, 231, 232, 233, 236–7, 244–5
 risk management and 259, 264, 266, 274, 275–6
 risk perception and 137, 139
 science-based approach and 189, 193–5
 SPS measures, trade impact 32, 33
Thailand – Cigarettes and 204, 205
see also Environmental Protection Agency; National Research Council
- US – Reformulated Gasoline* 250, 251, 254, 257
- validation, science-based approach 190–91
- values
 community, non-economic goals of health regulation and 69–70
 instrumental, defined 74–5
 intrinsic, defined 75
 role of *see* risk analysis, science and science and, relationship between 151
- variant Creutzfeldt-Jakob (vCJD) disease, risk perception and 134
- Venezuela 14–15, 33
- Victor, Favid G. 262
- Vogel, David 84
- voluntary standards, as non-tariff barrier to trade 15
- Wagner, Wendy 152
- Walker, Vern 183, 240–41
- Walzer, M. 70
- Wiener, Jonathon B. 46
- Wildavsky, A. 129, 166
- Wilkinson, Susan B.T. 140
- Williams, Pamela R.D. 163
- willpower *see* bounded willpower
- Wilson, J.S. 31
- Wong, K.-Y. 31
- Wooldridge, Dr 281–3
- World Health Organization (WHO)
 Constitution 10, 11, 70–71
EC – Hormones and 209, 212
 food safety and 40
 health/trade conflict identification and 98
 right to health as fundamental human right 71, 91
 risk assessment and 230
 science-based approach and 288
Thailand – Cigarettes and 205
- World Trade Organization (WTO)
 cases *see* *Australia – Salmon*; *Brazil – Retreaded Tyres*; *EC – Asbestos*; *EC – Biotech products*; *EC – Hormones*; *Japan – Agricultural products*; *Japan – Apples*; *Korea – Beef*; *Thailand – Cigarettes*; *US – Reformulated Gasoline*
 health definition and 10
 health/trade conflict and 51, 90
 case for trade 58
 health regulation 59
 identification 92, 94, 95
 resolution 100–102, 103, 107
 non-tariff barriers and 12
 North-South conflict and 47
 regulatory decision-making and 42
 review standard and 276, 277, 278
 risk analysis and 143, 145, 154, 155, 166, 168, 175
 risk perception and 127, 141–2
 science-based approach and 181
 assessing 183–91
 domestic regulatory decisions, reviewing 191–201
 standard setting and 111, 113, 122, 126
see also General Agreement on Tariffs and Trade; SPS Agreement
- Yandle, B. *see* Baptist–Bootlegger theory
- Zambia 47
see also Africa
- Zarrilli, Simonetta 47
- Ziman, John 147